Ocular Therapeutix, INC Schedule 13G passive stakes

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 9.53% of Ocular Therapeutix, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Ocular Therapeutix Inc. due to an internal corporate realignment.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a beneficial ownership of 5.13% in Ocular Therapeutix, Inc.

Deep Track Capital and its affiliates have reported a beneficial ownership of 4.31% in Ocular Therapeutix, Inc., indicating a reduction below the 5% threshold.

Summer Road LLC, a Delaware family office, has reported a 5.7% beneficial ownership stake in Ocular Therapeutix, Inc., totaling 12,134,357 common shares.

Venrock Healthcare Capital Partners and affiliates report a 7.3% beneficial ownership stake in Ocular Therapeutix Inc., totaling 12.9 million shares.

Deep Track Capital, along with its affiliates, has disclosed a 6.18% beneficial ownership stake in Ocular Therapeutix, Inc. as of September 30, 2025.

FMR LLC and Abigail P. Johnson have reported an aggregate beneficial ownership of 15.0% of Ocular Therapeutix Inc.'s common stock as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.8% beneficial ownership stake in Ocular Therapeutix, Inc. as of September 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 12.3% of Ocular Therapeutix Inc.'s common stock as of June 30, 2025.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a 9.65% beneficial ownership stake in Ocular Therapeutix, Inc., totaling 15,458,138 shares.

Opaleye Management Inc. has filed an Amendment No. 6 to its Schedule 13G, disclosing a reduced beneficial ownership of 2.76% in Ocular Therapeutix, Inc. common stock as of December 31, 2024.